` SAVA (Cassava Sciences Inc) vs S&P 500 Comparison - Alpha Spread

SAVA
vs
S&P 500

Over the past 12 months, SAVA has underperformed S&P 500, delivering a return of -91% compared to the S&P 500's 12% growth.

Stocks Performance
SAVA vs S&P 500

Loading
SAVA
S&P 500
Add Stock

Performance Gap
SAVA vs S&P 500

Loading
SAVA
S&P 500
Difference

Performance By Year
SAVA vs S&P 500

Loading
SAVA
S&P 500
Add Stock

Competitors Performance
Cassava Sciences Inc vs Peers

S&P 500
SAVA
LLY
JNJ
NOVO B
ROG
Add Stock

Cassava Sciences Inc
Glance View

Market Cap
101m USD
Industry
Pharmaceuticals

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. The company is headquartered in Austin, Texas and currently employs 24 full-time employees. The company went IPO on 2000-07-14. The firm is focused on developing the drug for the treatment of neurodegenerative diseases, such as Alzheimer's disease. The Company’s products include Simufilam and SavaDx. Its lead therapeutic product candidate, Simufilam, is a proprietary small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer's brain. The SavaDx, is an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. The company is also developing SavaDx is a quantitative blood-based investigational biomarker/diagnostic to detect and monitor Alzheimer's disease. The Company’s scientific approach for the treatment of Alzheimer's disease seeks to simultaneously progress both neurodegeneration and neuroinflammation.

SAVA Intrinsic Value
Not Available
Back to Top